Company Profile
Teva Pharmaceutical Industries Stock Price, News & Catalysts
- Ticker:
- TEVA
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- Israel and listed in the U
Stock performance
39.31 USD (-0.73%)
Close
Last updated: October 1, 2026
38.5B USD
Market cap
Why the stock is moving
The latest monitored company update is “Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome.” The corresponding closing-price reaction is not yet available.
Company overview
Global Branded and Generic Medicines Company
Teva Pharmaceutical Industries is a global pharmaceutical company with businesses in innovative medicines, generic drugs, biosimilars, and active pharmaceutical ingredients. Its commercial reach spans North America, Europe, and international markets, supported by large-scale manufacturing and regulatory capabilities.
Core Innovative Brands
Teva's principal innovative growth brands are AUSTEDO for movement disorders, AJOVY for migraine prevention, and UZEDY, a long-acting risperidone formulation for schizophrenia. These products are shifting the company's portfolio toward specialty medicines with differentiated clinical profiles and longer commercial duration.
Neuroscience Pipeline
The neuroscience pipeline includes ecopipam for pediatric Tourette syndrome and a long-acting injectable formulation of olanzapine for schizophrenia. Together with UZEDY, these programs are intended to establish a broader franchise spanning movement disorders and long-acting psychiatric treatments.
Immunology Development
Teva is developing duvakitug, an anti-TL1A antibody partnered with Sanofi, in ulcerative colitis, Crohn's disease, and additional inflammatory disorders. TEV-408, an anti-IL-15 antibody designed for infrequent subcutaneous dosing, is being advanced in vitiligo.
Generics and Biosimilars Platform
Generic medicines remain a large part of Teva's business and provide global scale across dosage forms and therapeutic areas. The company is expanding its biosimilar portfolio through internal programs and partnerships, including products in ophthalmology, immunology, and neurology.
Future catalysts
- Potential U.S. launch of olanzapine long-acting injectable in the fourth quarter of 2026, subject to regulatory approval.
- Initiation of a Phase 2 study of TEV-408 in vitiligo in the fourth quarter of 2026.
- FDA review of the submitted NDA for ecopipam in pediatric Tourette syndrome.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Teva Pharmaceutical Industries (TEVA)?
Teva Pharmaceutical Industries (TEVA) most recently closed at 39.31 USD, a -0.73% move versus the previous session.
What is the market cap of Teva Pharmaceutical Industries (TEVA)?
Teva Pharmaceutical Industries currently has a market capitalization of 38.5B USD on BioPharmSignal.
What does Teva Pharmaceutical Industries do?
Global Branded and Generic Medicines Company Teva Pharmaceutical Industries is a global pharmaceutical company with businesses in innovative medicines, generic drugs, biosimilars, and active pharmaceutical ingredients. Its commercial reach spans North America, Europe, and international markets, supported by large-scale manufacturing and regulatory...
On which exchange is TEVA stock listed?
Teva Pharmaceutical Industries (TEVA) is associated with NYSE, Israel and listed in the U, Biopharma.
What is TEV-408?
Initiation of a Phase 2 study of TEV-408 in vitiligo in the fourth quarter of 2026.
Which conditions is Teva Pharmaceutical Industries targeting with TEV-408?
Teva Pharmaceutical Industries is associated with immunology, neuroscience, neurology based on its company overview and current catalyst commentary.
How does Teva Pharmaceutical Industries describe recent progress with TEV-408?
Initiation of a Phase 2 study of TEV-408 in vitiligo in the fourth quarter of 2026.
What is IL-15?
TEV-408, an anti-IL-15 antibody designed for infrequent subcutaneous dosing, is being advanced in vitiligo.